These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17914322)

  • 1. Ethics of the early intervention in the treatment of schizophrenia.
    Filaković P; Degmecić D; Koić E; Benić D
    Psychiatr Danub; 2007 Sep; 19(3):209-15. PubMed ID: 17914322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward a better identification and treatment of schizophrenia prodrome.
    Bota RG; Sagduyu K; Filin EE; Bota DA; Munro S
    Bull Menninger Clin; 2008; 72(3):210-27. PubMed ID: 18990056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dilemma of early drug intervention in prepsychotic illnesses of adolescence].
    Branik E; Meng H
    Prax Kinderpsychol Kinderpsychiatr; 2003 Dec; 52(10):751-65. PubMed ID: 14699785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase.
    Weiser M
    Am J Psychiatry; 2011 Aug; 168(8):761-3. PubMed ID: 21813489
    [No Abstract]   [Full Text] [Related]  

  • 5. Is oestrogen neuroprotective?
    Agius M; Hockings H; Wilson C; Lane D
    Psychiatr Danub; 2009 Sep; 21 Suppl 1():120-7. PubMed ID: 19789496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The staging model in schizophrenia, and its clinical implications.
    Agius M; Goh C; Ulhaq S; McGorry P
    Psychiatr Danub; 2010 Jun; 22(2):211-20. PubMed ID: 20562749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pre-psychotic states--contemporary diagnostic and therapeutic issues. Part II. The biological markers of the risk of schizophrenia. Therapy of pre-psychotic states].
    Szulc A; Czernikiewicz A
    Psychiatr Pol; 2007; 41(1):17-27. PubMed ID: 17494411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Early intervention in increased risk for schizophrenic illnesses. Multimodal psychotherapy--antipsychotic drugs only in treatment failure].
    Wieneke A; Bechdolf A; Schultze-Lutter F
    MMW Fortschr Med; 2000 Mar; 142(10):30-2. PubMed ID: 10748600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of the schizophrenia prodrome: is it presently ethical?
    Cornblatt BA; Lencz T; Kane JM
    Schizophr Res; 2001 Aug; 51(1):31-8. PubMed ID: 11479063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of untreated psychosis and it's effect on the symptomatic recovery in schizophrenia - preliminary results.
    Novak Sarotar B; Pesek MB; Agius M; Kocmur M
    Neuro Endocrinol Lett; 2008 Dec; 29(6):990-4. PubMed ID: 19112411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is antipsychotic medication stigmatizing for people with mental illness?
    Sajatovic M; Jenkins JH
    Int Rev Psychiatry; 2007 Apr; 19(2):107-12. PubMed ID: 17464788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Schizophrenics in the doctor's office. Diagnostic and therapeutic aspects].
    Bottlender R; Möller HJ
    MMW Fortschr Med; 2004 May; 146 Spec No 2():19-23. PubMed ID: 15376697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and outcomes in adolescents with schizophrenia.
    Schulz SC; Findling RL; Friedman L; Kenny JT; Wise AL
    J Clin Psychiatry; 1998; 59 Suppl 1():50-4; discussion 55-6. PubMed ID: 9448669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia.
    Mittal VA; Neumann C; Saczawa M; Walker EF
    Arch Gen Psychiatry; 2008 Feb; 65(2):165-71. PubMed ID: 18250254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis.
    Ruhrmann S; Bechdolf A; Kühn KU; Wagner M; Schultze-Lutter F; Janssen B; Maurer K; Häfner H; Gaebel W; Möller HJ; Maier W; Klosterkötter J;
    Br J Psychiatry Suppl; 2007 Dec; 51():s88-95. PubMed ID: 18055944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating schizotaxia and its place in studies of preventing schizophrenia by psychopharmacological intervention.
    Tsuang MT; Stone WS; Tarbox SI; Faraone SV
    Essent Psychopharmacol; 2005; 6(2):91-103. PubMed ID: 15765793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of psychopharmacotherapy in improving the long-term outcome of schizophrenia.
    Alam DA; Janicak PG
    Essent Psychopharmacol; 2005; 6(3):127-40. PubMed ID: 15869020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey.
    Deurell M; Weischer M; Pagsberg AK; Labianca J
    Nord J Psychiatry; 2008; 62(6):472-80. PubMed ID: 18841508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection and treatment of schizophrenia: how early?
    Riecher-Rössler A; Gschwandtner U; Borgwardt S; Aston J; Pflüger M; Rössler W
    Acta Psychiatr Scand Suppl; 2006; (429):73-80. PubMed ID: 16445487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.
    Lieberman JA; Malaspina D; Jarskog LF
    CNS Spectr; 2006 Apr; 11(4):suppl 1-13; quiz suppl 14-5. PubMed ID: 16641837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.